{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:54:58Z","timestamp":1772582098640,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11894-025-00987-3","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T03:27:35Z","timestamp":1749007655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations"],"prefix":"10.1007","volume":"27","author":[{"given":"Sarah","family":"Rotondo-Trivette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"987_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","volume":"25","author":"HH Uhlig","year":"2006","unstructured":"Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309\u201318.","journal-title":"Immunity"},{"key":"987_CR2","doi-asserted-by":"publisher","first-page":"e0288351","DOI":"10.1371\/journal.pone.0288351","volume":"18","author":"GK Hui","year":"2023","unstructured":"Hui GK, Gao X, Gor J, Lu J, Sun PD, Perkins SJ. The solution structure of the unbound IgG Fc receptor CD64 resembles its crystal structure: implications for function. PLoS ONE. 2023;18:e0288351.","journal-title":"PLoS ONE"},{"key":"987_CR3","doi-asserted-by":"publisher","first-page":"1532852","DOI":"10.3389\/fimmu.2025.1532852","volume":"16","author":"KL Sachen","year":"2025","unstructured":"Sachen KL, Hammaker D, Sarabia I, et al. Guselkumab binding to CD64\u2009+\u2009IL-23\u2013producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. 2025;16:1532852.","journal-title":"Front Immunol"},{"key":"987_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20061099","volume":"203","author":"S Hue","year":"2006","unstructured":"Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell\u2013mediated intestinal inflammation. J Exp Med. 2006;203:2473\u201383.","journal-title":"J Exp Med"},{"key":"987_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N, Alimentiv Translational Research Consortium (ATRC). IL-12 and IL-23 pathway Inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20:433\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"987_CR6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, et al. A Genome-Wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461\u20133.","journal-title":"Science"},{"key":"987_CR7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"987_CR8","unstructured":"STELARA\u00ae (ustekinumab).| Healthcare Professional Website. In: STELARA\u00ae (ustekinumab). https:\/\/www.stelarahcp.com\/crohns-disease\/dosing-and-administration. Accessed 20 Jan 2025."},{"key":"987_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cgh.2023.06.014","volume":"22","author":"J-F Colombel","year":"2024","unstructured":"Colombel J-F, Sands BE, Gasink C, et al. Evolution of symptoms after ustekinumab induction therapy in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2024;22:144\u2013e1532.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","volume":"19","author":"JE Ollech","year":"2021","unstructured":"Ollech JE, Normatov I, Peleg N, et al. Effectiveness of ustekinumab dose escalation in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2021;19:104\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/apt.15784","volume":"52","author":"U Kopylov","year":"2020","unstructured":"Kopylov U, Hanzel J, Liefferinckx C, et al. Effectiveness of ustekinumab dose escalation in Crohn\u2019s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020;52:135\u201342.","journal-title":"Aliment Pharmacol Ther"},{"key":"987_CR12","doi-asserted-by":"publisher","first-page":"175628482095924","DOI":"10.1177\/1756284820959245","volume":"13","author":"SA Haider","year":"2020","unstructured":"Haider SA, Yadav A, Perry C, et al. Ustekinumab dose escalation improves clinical responses in refractory Crohn\u2019s disease. Th Adv Gastroenterol. 2020;13:1756284820959245.","journal-title":"Th Adv Gastroenterol"},{"key":"987_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","volume":"118","author":"AM Johnson","year":"2023","unstructured":"Johnson AM, Barsky M, Ahmed W, et al. The Real-World effectiveness and safety of ustekinumab in the treatment of Crohn\u2019s disease: results from the SUCCESS consortium. Official J Am Coll Gastroenterol| ACG. 2023;118:317.","journal-title":"Official J Am Coll Gastroenterol| ACG"},{"key":"987_CR14","doi-asserted-by":"publisher","first-page":"i69","DOI":"10.1093\/ecco-jcc\/jjae190.0035","volume":"19","author":"MDPD Bossuyt","year":"2025","unstructured":"Bossuyt MDPD, Rahier P, Baert JF F, et al. OP35 low remission recapture after ustekinumab dose optimization in Crohn\u2019s disease: results of the randomized placebo-controlled double-blind rescue study. J Crohn\u2019s Colitis. 2025;19:i69\u201370.","journal-title":"J Crohn\u2019s Colitis"},{"key":"987_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","volume":"136","author":"JG Krueger","year":"2015","unstructured":"Krueger JG, Ferris LK, Menter A, et al. Anti\u2013IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136:116\u2013e1247.","journal-title":"J Allergy Clin Immunol"},{"key":"987_CR16","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015\u201330.","journal-title":"Lancet"},{"key":"987_CR17","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031\u201346.","journal-title":"Lancet"},{"key":"987_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ecco-jcc\/jjad206","volume":"18","author":"J-F Colombel","year":"2023","unstructured":"Colombel J-F, Schreiber S, D\u2019Haens G, et al. Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn\u2019s disease: post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY phase 3 studies. J Crohns Colitis. 2023;18:818\u201327.","journal-title":"J Crohns Colitis"},{"key":"987_CR19","unstructured":"Zinger A, Choi D, Choi N, Fear E, Fine Z, Cohen RD, Rubin DT. (2024) Long-term effectiveness and safety of Risankizumab in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol S1542-3565(24)00968\u20136."},{"key":"987_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel J-F, et al. Risankizumab versus ustekinumab for Moderate-to-Severe Crohn\u2019s disease. N Engl J Med. 2024;391:213\u201323.","journal-title":"N Engl J Med"},{"key":"987_CR21","doi-asserted-by":"publisher","first-page":"S1076","DOI":"10.14309\/01.ajg.0001035328.04327.b3","volume":"119","author":"R Dalal","year":"2024","unstructured":"Dalal R, Cabral H, Carlin A, Allegretti JR. S1490 dose intensification of Risankizumab for Crohn\u2019s disease: access and outcomes. Official J Am Coll Gastroenterol| ACG. 2024;119:S1076.","journal-title":"Official J Am Coll Gastroenterol| ACG"},{"key":"987_CR22","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, et al. Efficacy and safety of Mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404:2423\u201336.","journal-title":"Lancet"},{"key":"987_CR23","doi-asserted-by":"publisher","first-page":"i87","DOI":"10.1093\/ecco-jcc\/jjae190.0044","volume":"19","author":"S Vermeire","year":"2025","unstructured":"Vermeire S, Sands BE, D\u2019Haens G, et al. DOP005 Long-term efficacy and safety of Mirikizumab treatment for Crohn\u2019s disease: results from the VIVID-2 open-label extension study. J Crohn\u2019s Colitis. 2025;19:i87\u20139.","journal-title":"J Crohn\u2019s Colitis"},{"key":"987_CR24","unstructured":"Efficacy And Safety of Guselkumab Therapy in. Patients with moderately to severely active Crohn\u2019s disease: results of the Galaxi 2 & 3 phase 3 studies. ACR Meeting Abstracts."},{"key":"987_CR25","unstructured":"ACG 2024 Annual Meeting. https:\/\/acg2024.eventscribe.net\/fsPopup.asp?efp=RUdBRlNZSUoyMjI3Mg&PresentationID=1498104&rnd=0.9626783&mode=presInfo. Accessed 17 Mar 2025."},{"key":"987_CR26","doi-asserted-by":"publisher","first-page":"S740","DOI":"10.14309\/01.ajg.0001033576.85427.3d","volume":"119","author":"R Panaccione","year":"2024","unstructured":"Panaccione R, Hart A, Steinwurz F, et al. S1052 efficacy and safety of subcutaneous Guselkumab induction therapy in patients with moderately to severely active Crohn\u2019s disease: results through week 48 from the phase 3 GRAVITI study. Official J Am Coll Gastroenterol| ACG. 2024;119:S740.","journal-title":"Official J Am Coll Gastroenterol| ACG"},{"key":"987_CR27","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1111\/bcp.15364","volume":"88","author":"L Tran","year":"2022","unstructured":"Tran L, Yao Z, Xu Z, Vermeulen A. Population pharmacokinetics analysis of Guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis. Br J Clin Pharmacol. 2022;88:4481\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"987_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"987_CR29","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.cgh.2021.03.028","volume":"20","author":"RS Dalal","year":"2022","unstructured":"Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR. Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: A multicenter cohort study. Clin Gastroenterol Hepatol. 2022;20:2399\u2013e24014.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/ibd\/izac164","volume":"29","author":"RS Dalal","year":"2023","unstructured":"Dalal RS, Pruce JC, Allegretti JR. Long-Term outcomes after ustekinumab dose intensification for inflammatory bowel diseases. Inflamm Bowel Dis. 2023;29:830\u20133.","journal-title":"Inflamm Bowel Dis"},{"key":"987_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.14309\/ajg.0000000000002621","volume":"119","author":"W Afif","year":"2024","unstructured":"Afif W, Arasaradnam RP, Abreu MT, et al. Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: final results of the UNIFI Long-Term maintenance study. Am J Gastroenterol. 2024;119:910\u201321.","journal-title":"Am J Gastroenterol"},{"key":"987_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MEG.0000000000002939","volume":"37","author":"P Molander","year":"2025","unstructured":"Molander P, Af Bj\u00f6rkesten C-G, Henricson H, et al. Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study. Eur J Gastroenterol Hepatol. 2025;37:446\u201353.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"987_CR33","unstructured":"Risankizumab for Ulcerative Colitis. Two Randomized Clinical Trials| Gastroenterology| JAMA| JAMA Network. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2821291#google_vignette. Accessed 26 Feb 2025."},{"key":"987_CR34","doi-asserted-by":"publisher","first-page":"jjaf005","DOI":"10.1093\/ecco-jcc\/jjaf005","volume":"19","author":"R Panaccione","year":"2025","unstructured":"Panaccione R, Louis E, Colombel J-F, et al. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025;19:jjaf005.","journal-title":"J Crohns Colitis"},{"key":"987_CR35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/cpt.3330","volume":"116","author":"N Thakre","year":"2024","unstructured":"Thakre N, Goebel A, Winzenborg I, Suleiman AA, D\u2019Cunha R, Mensing S, Liu W, Pang Y. Population Pharmacokinetic and Exposure\u2013Response modeling to inform Risankizumab dose selection in patients with ulcerative colitis. Clin Pharmacol Ther. 2024;116:847\u201357.","journal-title":"Clin Pharmacol Ther"},{"key":"987_CR36","unstructured":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis| New England. Journal of Medicine. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2207940. Accessed 26 Feb 2025."},{"key":"987_CR37","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/ecco-jcc\/jjae088","volume":"18","author":"S Danese","year":"2024","unstructured":"Danese S, Dignass A, Matsuoka K, et al. Early and sustained symptom control with Mirikizumab in patients with ulcerative colitis in the phase 3 LUCENT programme. J Crohns Colitis. 2024;18:1845\u201356.","journal-title":"J Crohns Colitis"},{"key":"987_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","volume":"405","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Allegretti JR, Pan\u00e9s J, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405:33\u201349.","journal-title":"Lancet"},{"key":"987_CR39","unstructured":"TREMFYA\u00ae (guselkumab) HCP. https:\/\/www.tremfyahcp.com\/ulcerative-colitis\/efficacy\/. Accessed 3 Mar 2025."},{"key":"987_CR40","unstructured":"(2025) TREMFYA\u00ae (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis. In: JNJ.com. https:\/\/www.jnj.com\/media-center\/press-releases\/tremfya-guselkumab-subcutaneous-sc-induction-data-support-potential-to-be-the-first-and-only-in-its-class-to-offer-the-option-of-both-intravenous-and-sc-induction-therapy-in-ulcerative-colitis. Accessed 3 Mar 2025."},{"key":"987_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","volume":"166","author":"EL Barnes","year":"2024","unstructured":"Barnes EL, Agrawal M, Syal G, et al. AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders. Gastroenterology. 2024;166:59\u201385.","journal-title":"Gastroenterology"},{"key":"987_CR42","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","volume":"388","author":"S Travis","year":"2023","unstructured":"Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the treatment of chronic pouchitis. N Engl J Med. 2023;388:1191\u2013200.","journal-title":"N Engl J Med"},{"key":"987_CR43","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.cgh.2024.04.030","volume":"22","author":"A Outtier","year":"2024","unstructured":"Outtier A, Louis E, Dewit O, et al. Efficacy and safety of ustekinumab for chronic pouchitis: A prospective Open-label multicenter study. Clin Gastroenterol Hepatol. 2024;22:2468\u2013e24741.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/1346-8138.14816","volume":"46","author":"K Ezzedine","year":"2019","unstructured":"Ezzedine K, Visseaux L, Cadiot G, Brixi H, Bernard P, Reguiai Z. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-\u03b1 agents in patients with inflammatory bowel diseases: A single-center retrospective study. J Dermatol. 2019;46:322\u20137.","journal-title":"J Dermatol"},{"key":"987_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/bjd\/ljad010","volume":"188","author":"K Dudink","year":"2023","unstructured":"Dudink K, Bouwman K, Chen Y, et al. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Br J Dermatol. 2023;188:601\u20139.","journal-title":"Br J Dermatol"},{"key":"987_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1346-8138.17031","volume":"51","author":"K Yamanaka","year":"2024","unstructured":"Yamanaka K. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review. J Dermatol. 2024;51:172\u20139.","journal-title":"J Dermatol"},{"key":"987_CR47","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/iwj.13359","volume":"17","author":"B Burgdorf","year":"2020","unstructured":"Burgdorf B, Schlott S, Ivanov IH, Dissemond J. Successful treatment of a refractory pyoderma gangrenosum with Risankizumab. Int Wound J. 2020;17:1086\u20138.","journal-title":"Int Wound J"},{"key":"987_CR48","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","volume":"125","author":"KL Pepple","year":"2018","unstructured":"Pepple KL, Lin P. Targeting Interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology. 2018;125:1977\u201383.","journal-title":"Ophthalmology"},{"key":"987_CR49","doi-asserted-by":"publisher","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","volume":"60","author":"P Mease","year":"2021","unstructured":"Mease P, van den Bosch F. IL-23 and axial disease: do they come together? Rheumatology. 2021;60:iv28\u201333.","journal-title":"Rheumatology"},{"key":"987_CR50","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Agarwal SK, Ilivanova E, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and Guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017;76:831\u20139.","journal-title":"Ann Rheum Dis"},{"key":"987_CR51","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41575-023-00758-3","volume":"20","author":"MN Brondfield","year":"2023","unstructured":"Brondfield MN, Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol. 2023;20:504\u201323.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"987_CR52","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1007\/s10620-015-3677-x","volume":"60","author":"A O\u2019Toole","year":"2015","unstructured":"O\u2019Toole A, Nwanne O, Tomlinson T. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: A Meta-Analysis. Dig Dis Sci. 2015;60:2750\u201361.","journal-title":"Dig Dis Sci"},{"key":"987_CR53","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ajg.2008.71","volume":"104","author":"SV Kane","year":"2009","unstructured":"Kane SV, Acquah LA. Placental transport of Immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228\u201333.","journal-title":"Am J Gastroenterol"},{"key":"987_CR54","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","volume":"16","author":"K Mitrova","year":"2022","unstructured":"Mitrova K, Pipek B, Bortlik M, et al. Safety of ustekinumab and Vedolizumab during Pregnancy-Pregnancy, neonatal, and infant outcome: A prospective multicentre study. J Crohns Colitis. 2022;16:1808\u201315.","journal-title":"J Crohns Colitis"},{"key":"987_CR55","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0140-6736(24)00052-7","volume":"403","author":"OH Nielsen","year":"2024","unstructured":"Nielsen OH, Gubatan JM, Kolho K-L, Streett SE, Maxwell C. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. Lancet. 2024;403:1291\u2013303.","journal-title":"Lancet"},{"key":"987_CR56","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1159\/000524199","volume":"238","author":"PP Naik","year":"2022","unstructured":"Naik PP. Adverse effects of Anti-Interleukin-23 agents employed in patients with psoriasis: A systematic review. Dermatology. 2022;238:886\u201396.","journal-title":"Dermatology"},{"key":"987_CR57","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","volume":"71","author":"X Huang","year":"2023","unstructured":"Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, Zhu H. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71:505\u201315.","journal-title":"Immunol Res"},{"key":"987_CR58","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","volume":"21","author":"V Solitano","year":"2023","unstructured":"Solitano V, Facciorusso A, Jess T, Ma C, Hassan C, Repici A, Jairath V, Armuzzi A, Singh S. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: A systematic review and Meta-Analysis. Clin Gastroenterol Hepatol. 2023;21:907\u2013e9212.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR59","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/ibd\/izy313","volume":"25","author":"B Click","year":"2019","unstructured":"Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis. 2019;25:831\u201342.","journal-title":"Inflamm Bowel Dis"},{"key":"987_CR60","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"N Terrault","year":"2018","unstructured":"Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M, Brown R, Bzowej N, Wong J. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"987_CR61","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.dld.2017.09.002","volume":"49","author":"C Abreu","year":"2017","unstructured":"Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. Dig Liver Disease. 2017;49:1289\u201397.","journal-title":"Dig Liver Disease"},{"key":"987_CR62","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399:2200\u201311.","journal-title":"Lancet"},{"key":"987_CR63","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/ecco-jcc\/jjae063","volume":"18","author":"M Fumery","year":"2024","unstructured":"Fumery M, Serrero M, Bouguen G, et al. Real-World comparison of the effectiveness between ustekinumab and Vedolizumab in patients with ulcerative colitis exposed to at least one Anti-TNF agent. J Crohns Colitis. 2024;18:1615\u201321.","journal-title":"J Crohns Colitis"},{"key":"987_CR64","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","volume":"21","author":"T Straatmijer","year":"2023","unstructured":"Straatmijer T, Biemans VBC, Visschedijk M, et al. Superior effectiveness of Tofacitinib compared to Vedolizumab in Anti-TNF-experienced ulcerative colitis patients: A nationwide Dutch registry study. Clin Gastroenterol Hepatol. 2023;21:182\u2013e1912.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR65","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cgh.2023.08.021","volume":"22","author":"RS Dalal","year":"2024","unstructured":"Dalal RS, Kallumkal G, Cabral HJ, Bachour S, Barnes EL, Allegretti JR. Comparative effectiveness of Upadacitinib vs ustekinumab for ulcerative colitis: A multicenter retrospective cohort study. Clin Gastroenterol Hepatol. 2024;22:666\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"987_CR66","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.3748\/wjg.v28.i47.6743","volume":"28","author":"D Balderramo","year":"2022","unstructured":"Balderramo D. Role of the combination of biologics and\/or small molecules in the treatment of patients with inflammatory bowel disease. World J Gastroenterol. 2022;28:6743\u201351.","journal-title":"World J Gastroenterol"},{"key":"987_CR67","doi-asserted-by":"publisher","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","volume":"360 4","author":"QA Alayo","year":"2022","unstructured":"Alayo QA, Fenster M, Altayar O, et al. Systematic review with Meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease. Crohns Colitis. 2022;360 4:otac002.","journal-title":"Crohns Colitis"},{"key":"987_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Pan\u00e9s J, VEGA Study Group. Guselkumab plus golimumab combination therapy versus Guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"987_CR69","doi-asserted-by":"publisher","DOI":"10.21037\/dmr-22-80","author":"A Chaar","year":"2023","unstructured":"Chaar A, Atiyat R, Al-Bawardy B. Therapeutic drug monitoring of ustekinumab and Vedolizumab in inflammatory bowel disease: worth the draw? Dig Med Res. 2023. https:\/\/doi.org\/10.21037\/dmr-22-80.","journal-title":"Dig Med Res"},{"key":"987_CR70","first-page":"250","volume":"60","author":"K Dutt","year":"2024","unstructured":"Dutt K, Vasudevan A. Therapeutic drug monitoring for biologic and Small-Molecule therapies for inflammatory bowel disease. Med (Kaunas). 2024;60:250.","journal-title":"Med (Kaunas)"},{"key":"987_CR71","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.cgh.2024.03.039","volume":"22","author":"X Roblin","year":"2024","unstructured":"Roblin X, Moschetti E, Barrau M, Cheifetz AS, Papamichael K, Paul S. Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2024;22:2340\u2013e23432.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-00987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-00987-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-00987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:03:56Z","timestamp":1772579036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-00987-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-00987-3","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"24 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sarah Rotondo-Trivette and William Jennings have no competing interests to report. David Fudman reports advisory board fees from Pfizer, Fresenius Kabi and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"35"}}